InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 36 genes relevant to the care of patients with advanced NSCLC

InVisionFirst-Lung® is available world-wide for both commercial and research use. In the US, InVisionFirst-Lung is now covered for Medicare patients with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.

36 gene panel including NSCLC markers

Support the prognosis and therapeutic decisions in patients diagnosed with NSCLC

ALKBRAFEGFRERBB2 (HER2)
KRASMETROS1STK11
VIEW FULL GENE LIST

Alterations associated with:
a) an FDA approved drug for another tumor type,
b) inclusion or exclusion criteria for clinical trials and/or,
c) indicators for resistance to therapy.

 

AKT1CCND1CDKN2ACTNNB1ESR1FGFR1FGFR2
FGFR3GATA3GNA11GNAQGNASHRASIDH1
IDH2KITMAP2K1MYCNFE2L2NRASNTRK1
NTRK3PDGFRAPIK3CAPPP2R1APTENTP53U2AF1
SNVs + Indels - Hotspot Regions
Fusions + SNVs + Indels
CNVs + SNVs + Indels

8 actionable genes relevant to advanced NSCLC  in a panel of 36 genes

  • EGFR, ALK, ROS1 and BRAF for FDA-approved targeted therapies
  • MET and ERBB2 (HER2) as recommended by CAP/AMP/ASCO/IASLC guidelines
  • KRAS and STK11 for prognostic and therapeutic value as described in clinical literature

Largest prospective molecular diagnostics study in NSCLC published up to date in JCO Precision Oncology

98% concordance

observed with matched tissue profiling

InVisionFirst-Lung provided access to comprehensive genetic profiling (CGP) when tissue was not available

26% more actionable alterations

detected versus standard-of-care tissue testing

Our technology brings high sensitivity and specificity to drive appropriate treatment choice

InVision® Platform can detect single nucleotide variants (SNVs), small insertions and deletions (InDels), copy number variant (CNVs), and structural variants (SV) such as fusions from plasma cell free DNA (cfDNA) with a detection range as low as 0.1% variant allele fraction with a mean read depth of 70,000.

Click here for InVisionFirst®-Lung clinical validation results and clinical utility data.

Results within 7 calendar days from blood draw

  • Test results are delivered through a secure Clinician Portal
  • The report includes genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials
  • This report can be easily exported and added to most electronic health records (EHRs)

InVisionFirst®-Lung can help at different stages:

 

At Diagnosis*

  • When results for EGFR single nucleotide variants (SNVs) and insertions and deletions (indels); rearrangements in ALK and ROS1; and SNVs for BRAF are not available AND
  • When tissue-based CGP is infeasible (i.e. quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated).

OR

At Progression*

  • For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK and ROS1; and SNVs for BRAFs, and for whom tissue-based CGP is infeasible; OR
  • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs).

* If no genetic alteration is detected by InVisionFirst®-Lung or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered

Advocating for patients with advanced NSCLC

Inivata offers the InVision® Access Program, a supportive patient assistance program for eligible patients, to help at every step along the way.